Cirrhotic ascites
Conditions
Interventions
Trial group:Conventional diuretics (furosemide 40mg + spironolactone 100mg once daily) + ascites concentration filtration reinfusion (A-CFRS) + immediate intravenous albumin 10g infusion
Control group:Conventional diuretics (furosemide 40mg + spironolactone 100mg once daily) + large-volume paracentesis (LVP) + human serum albumin 10g per day
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 75 years (inclusive), with no gender restrictions; 2. Meets the diagnostic criteria for moderate to massive ascites associated with liver cirrhosis as outlined in the "Guidelines for the Diagnosis and Treatment of Ascites Due to Liver Cirrhosis (2023 Edition)."; 3. After at least one week of treatment with conventional diuretics (40 mg of Furosemide + 100 mg of Spironolactone once daily) and an appropriate amount of human albumin, there has been a poor response to ascites treatment (decrease of less than one grade); 4. Capable of independent behavior, voluntarily willing to participate in the clinical study, and has signed a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. History of allergies to extracorporeal circulation equipment, blood purification devices, etc.; 2. Platelet count (PLT) less than 50 × 10^9/L; 3. Patients with liver failure (patients with acute-on-chronic liver failure should meet the criteria in the "Guidelines for the Diagnosis and Treatment of Acute-on-Chronic Liver Failure (2025 Edition)"; others should comply with the "Guidelines for the Diagnosis and Treatment of Liver Failure (2024 Edition)"). 4. Patients with gastrointestinal bleeding within the last two weeks; 5. Patients with hepatic encephalopathy grade II or higher; 6. Patients with severe heart or lung diseases; unstable vital signs; 7. Patients with renal insufficiency or other clear kidney diseases, with a glomerular filtration rate less than 50 ml/min/1.73 m^2 or urine output less than 800 ml/day; nephrotic syndrome. 8. Patients with chylous ascites; 9. Patients with hyperkalemia; 10. Patients with malignant tumors such as liver cancer, gastric cancer, or colon cancer; 11. Patients with a history of kidney or liver transplantation; 12. Individuals with a history of mental illness or substance abuse; 13. Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to ascites resolution; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of ascites resolution;Time to relief of abdominal distension symptoms and relief rate;Reduction in weight and abdominal circumference;Serum albumin;Child-Pugh score;MELD score;Demand for human albumin;Time to recurrence of moderate to massive ascites after treatment;Quality of life assessment;28-day and 90-day survival rates; | — |
Countries
China
Contacts
Public ContactChen Yu
Beijing You’an Hospital, Capital Medical University,
Outcome results
None listed